International research collaborations
VACCELERATE - European Corona Vaccine Trial Accelerator Platform
VACCELERATE aims to accelerate phase 2 & 3 COVID-19 vaccine trials. It is part of the European Commission “HERA incubator” program and it involves 29 partners both from EU-member states and EU-associated countries. VACCELERATE brings together different stakeholders involved in vaccine development across the EU to develop a platform for trial design and conduct. Its end goal is to develop a vaccine clinical trial network for the COVID-19 pandemic as well as to serve as point of reference for future emerging infectious diseases by playing a pivotal role in strengthening the vaccine development capacities of Europe.
VACCELERATE is 3-year project. It started in February 2021 and will terminate in February 2024. It has received funding from the European Union's Horizon 2020 programme (Grant Agreement no. 101037867).
CLEO is the National Coordinator for Greece, thereby acting as an ambassador of VACCELERATE and serving as the country’s point of contact. In this role, CLEO maps clinical trial sites and laboratories in Greece, while also adapting all VACCELERATE activities to national requirements and identifying the needs for education and capacity building across Greek vaccine trial sites.
CLEO is also the lead partner for the capacity mapping analysis of pediatric vaccine clinical trial sites across Europe. The main objectives are to map and analyze the capacity of these sites, collect and analyze past performance and define minimum quality standards with a focus on the standardization and harmonization of pediatric COVID-19 vaccine research, in order to develop or inform pediatric-specific vaccination programs future.
CLEO is also a co-lead and contributor to VACCELERATE research activities focused on understanding volunteer COVID-19 vaccine trial participation, especially among under-represented and hard-to-reach groups across Europe and EU-associated countries.
- Clinical trial sites interested in conducting COVID-19 vaccine studies can register to the EUVAP Platform https://www.euvap.eu/
- For individuals interested in signing up to upcoming COVID-19 vaccination studies, https://www.vaccelerate.eu/volunteer-registry/index.html
Read more about VACCELERATE, here.
Reducing Antimicrobial use and Nosocomial INfections in KIDS: A European Network (RANIN-KIDS)
RANIN-KIDS Network was founded in Athens, Greece, in March 2018, in collaboration with the European Society for Paediatric Infectious Diseases (ESPID) and ESGAP, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Antimicrobial stewardship. The long-term goal of RANIN-KIDS is to achieve optimal clinical outcomes among pediatric patients in Europe by fighting healthcare-acquired infections (HAIs) and reducing the inappropriate use of antibiotics.
Find out more about RANIN-KIDS, here.
Network of Neonatal Infections Supervision (neonIN)
The neonIN network is an international database developed by St. George Hospital of London that collects epidemiological data on neonatal infections based on confirmed positive cultures. The program started off in 4 London neonatal units in 2004. With CLEO as a partner, it expanded to Greece in 2013 in two of Athens’ paediatric hospitals, “Aghia Sophia” and “Panagiotis and Aglaia Kyriakou”.
Since then and up until December 2019, CLEO has been supporting the collection of data of 10 neonatal units out of the 18 currently participating in Greece. Findings from analyses of this network are frequently presented at international symposia. For more information click here.
Vaccine Acceptance in Botswana, the Dominican Republic, and Greece
In 2013 CLEO first took part in a multi-center study led by Kristen Feemster, MD, MPH, MSPHR, from the Children’s Hospital of Philadelphia (CHOP) in the United States, aimed at investigating societal attitudes toward preventative vaccination. Data collection span from October 2013 to February 2014. Results were published in an article entitled “The impact of access to immunization information on vaccine acceptance in three countries” 2017 in the PLoS One journal.
Sepsis, Prevalence, Outcomes and Therapies (SPROUT)
The SPROUT global multi-center research program investigated the epidemiology, treatments and outcomes of severe sepsis and septic shock in heavily afflicted babies and children. The SPROUT study, based at CHOP, comprised 505 participating centers from across the globe. Participants from Greece included the “Aghia Sophia” and the “Panagiotis and Aglaia Kyriakou” General Hospital Units for Children’s Intensive Treatment. Results of the study have been published in international scientific journals.
Antibiotic prescribing in Greece 2010-2013
CLEO was granted access to the Intercontinental Marketing Services (IMS) Health Inc. database for antibiotic prescriptions and sales. Specifically, data from 2010-2013 on antibiotic prescriptions for both children and adults in Greece were analyzed, with the objective of describing prescription patterns and estimating the annual cost of prescriptions to the insurance companies. The study results were presented at international symposia and published in scientific journals, for more information, take a look at CLEO's Publications.
Antibiotic Resistance and Prescribing in European Children (ARPEC)
CLEO participated in ARPEC an EU-funded multi-center pan-European study of antibiotic prescription for hospitalized children. A total of 84 hospitals from 19 European countries participated. Results of this study have been published in scientific journals, listed in CLEO's Publications.